Rob J. van Klaveren

6.5k total citations · 1 hit paper
84 papers, 4.4k citations indexed

About

Rob J. van Klaveren is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Rob J. van Klaveren has authored 84 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pulmonary and Respiratory Medicine, 23 papers in Radiology, Nuclear Medicine and Imaging and 15 papers in Oncology. Recurrent topics in Rob J. van Klaveren's work include Lung Cancer Diagnosis and Treatment (43 papers), Lung Cancer Treatments and Mutations (24 papers) and Radiomics and Machine Learning in Medical Imaging (15 papers). Rob J. van Klaveren is often cited by papers focused on Lung Cancer Diagnosis and Treatment (43 papers), Lung Cancer Treatments and Mutations (24 papers) and Radiomics and Machine Learning in Medical Imaging (15 papers). Rob J. van Klaveren collaborates with scholars based in Netherlands, Belgium and United States. Rob J. van Klaveren's co-authors include Harry J. de Koning, Mathias Prokop, Matthijs Oudkerk, Ernst T. Scholten, Jan P. van Meerbeeck, Giuseppe Giaccone, Hester A. Gietema, Willem P.Th.M. Mali, Karien A.M. van den Bergh and Christian Manegold and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Rob J. van Klaveren

83 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada

2005 474 citations Jan P. van Meerbeeck, Christian Manegold et al. profile →

Peers

Countries citing papers authored by Rob J. van Klaveren

Since Specialization

Citations

This map shows the geographic impact of Rob J. van Klaveren's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rob J. van Klaveren with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rob J. van Klaveren more than expected).

Fields of papers citing papers by Rob J. van Klaveren

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Rob J. van Klaveren. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rob J. van Klaveren. The network helps show where Rob J. van Klaveren may publish in the future.

Co-authorship network of co-authors of Rob J. van Klaveren

This figure shows the co-authorship network connecting the top 25 collaborators of Rob J. van Klaveren. A scholar is included among the top collaborators of Rob J. van Klaveren based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Rob J. van Klaveren. Rob J. van Klaveren is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Survivin Autoantibodies Are Not Elevated in Lung Cancer When Assayed Controlling for Specificity and Smoking Status 2016 ·Cancer Immunology Research ·(unknown), Martijn M. VanDuijn, Christoph Stingl, Lennard J. M. Dekker, Anastasios E. Germenis, Harry J. de Koning, Rob J. van Klaveren, Joachim G.J.V. Aerts, Jan Lindemans, Theo M. Luider	4
2	Lung Cancer Screening CT-Based Prediction of Cardiovascular Events 2013 ·JACC. Cardiovascular imaging ·Onno M. Mets, Rozemarijn Vliegenthart, Martijn J. A. Gondrie, Max A. Viergever, Matthijs Oudkerk, Harry J. de Koning, Willem P.Th.M. Mali, Mathias Prokop, Rob J. van Klaveren, Yolanda van der Graaf, Constantinus F. M. Buckens, Pieter Zanen, Jan‐Willem J. Lammers, Harry J.M. Groen, Ivana Išgum, Pim A. de Jong	89
3	Outcome of four-dimensional stereotactic radiotherapy for centrally located lung tumors 2012 ·Radiotherapy and Oncology ·Joost J. Nuyttens, Noëlle C. van der Voort van Zyp, J. Praag, Shafak Aluwini, Rob J. van Klaveren, Cornelis Verhoef, Peter M. T. Pattynama, Mischa S. Hoogeman	86
4	Chairperson's introduction 2011 ·European Journal of Cancer ·Rob J. van Klaveren	0
5	Screening and Early Detection of Lung Cancer 2011 ·The Cancer Journal ·(unknown), Rob J. van Klaveren	50
6	Screening for Lung Cancer with Digital Chest Radiography: Sensitivity and Number of Secondary Work-up CT Examinations 2010 ·Radiology ·Bartjan de Hoop, Cornelia Schaefer‐Prokop, Hester A. Gietema, Pim A. de Jong, Bram van Ginneken, Rob J. van Klaveren, Mathias Prokop	35
7	Informed participation in a randomised controlled trial of computed tomography screening for lung cancer 2009 ·European Respiratory Journal ·Karien A.M. van den Bergh, Marie‐Louise Essink‐Bot, Rob J. van Klaveren, Harry J. de Koning	45
8	The 15q24/25 Susceptibility Variant for Lung Cancer and Chronic Obstructive Pulmonary Disease Is Associated with Emphysema 2009 ·American Journal of Respiratory and Critical Care Medicine ·Diether Lambrechts, Ian Buysschaert, Pieter Zanen, Johan Coolen, Natacha Lays, Harry Cuppens, Harry J.M. Groen, (unknown), Rob J. van Klaveren, Johny Verschakelen, Cisca Wijmenga, Dirkje S. Postma, Marc Decramer, Wim Janssens	77
9	Volumetric measurement of pulmonary nodules at low-dose chest CT: effect of reconstruction setting on measurement variability 2009 ·European Radiology ·Ying Wang, Geertruida H. de Bock, Rob J. van Klaveren, (unknown), (unknown), Yingru Zhao, Monique D. Dorrius, Rozemarijn Vliegenthart Proença, Wendy J. Post, Matthijs Oudkerk	57
10	Single-Agent Pemetrexed for Chemonaïve and Pretreated Patients with Malignant Pleural Mesothelioma: Results of an International Expanded Access Program 2008 ·Journal of Thoracic Oncology ·Paul Taylor, B. Castagneto, G. Dark, M. Marangolo, Giorgio V. Scagliotti, Rob J. van Klaveren, Roberto Labianca, Monika Serke, Wolfgang Schuette, Jan P. van Meerbeeck, David F. Heigener, (unknown), Susumu Adachi, J. Blatter, Joachim von Pawel	39
11	Monitoring of Smoking-induced Emphysema with CT in a Lung Cancer Screening Setting: Detection of Real Increase in Extent of Emphysema 2007 ·Radiology ·Hester A. Gietema, Arnold M. R. Schilham, Bram van Ginneken, Rob J. van Klaveren, Jan Willem J. Lammers, Mathias Prokop	57
12	Neglectable benefit of searching for incidental findings in the Dutch--Belgian lung cancer screening trial (NELSON) using low-dose multidetector CT 2007 ·European Radiology ·(unknown), (unknown), (unknown), Dong Xu, Hester J. van der Zaag–Loonen, Erik J. van der Jagt, Rob J. van Klaveren, Matthijs Oudkerk	121
13	Risk‐based selection from the general population in a screening trial: Selection criteria, recruitment and power for the Dutch‐Belgian randomised lung cancer multi‐slice CT screening trial (NELSON) 2006 ·International Journal of Cancer ·Carola A. van Iersel, Harry J. de Koning, Gerrit Draisma, Willem P.Th.M. Mali, Ernst T. Scholten, Kristiaan Nackaerts, Mathias Prokop, J. Dik F. Habbema, Matthijs Oudkerk, Rob J. van Klaveren	376
14	Pulmonary Nodules Detected at Lung Cancer Screening: Interobserver Variability of Semiautomated Volume Measurements 2006 ·Radiology ·Hester A. Gietema, Ying Wang, Dongming Xu, Rob J. van Klaveren, Harry J. de Koning, Ernst T. Scholten, Johny Verschakelen, Gerhard Kohl, Matthijs Oudkerk, Mathias Prokop	94
15	Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma 2003 ·Lung Cancer ·Rob J. van Klaveren, Joachim G.J.V. Aerts, (unknown), Giuseppe Giaccone, Christian Manegold, Jan P. van Meerbeeck	89
16	Unexpected response of a pulmonary blastoma on radiotherapy: a case report and review of the literature 2002 ·Lung Cancer ·Veerle Surmont, Rob J. van Klaveren, Peter J.C.M. Nowak, Pieter E. Zondervan, Henk C. Hoogsteden, Jan P. van Meerbeeck	23
17	Role of reactive oxygen species in occupational and environmental obstructive pulmonary diseases 1999 ·Current Opinion in Pulmonary Medicine ·Rob J. van Klaveren, Benoît Nemery	29
18	Determinants of the hypercapnic and hypoxic response in normal man 1998 ·Respiration Physiology ·Rob J. van Klaveren, M. Demedts	31
19	Increase in γ-Glutamyltransferase by Glutathione Depletion in Rat Type II Pneumocytes 1997 ·Free Radical Biology and Medicine ·Rob J. van Klaveren, Peter Hoet, Jan Pype, Maurits Demedts, Benoît Nemery	85
20	Role of γ-glutamyltransferase in putrescine uptake by rat type II pneumocytes 1995 ·Biochemical Pharmacology ·Rob J. van Klaveren, Peter Hoet, Maurits Demedts, Benoît Nemery	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact